This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to our use of cookies. Please read our cookie notice for more information on the cookies we use and how to delete or block them.

Bookmark Email Print page

Global life sciences sector positioned for success in 2014

New York, Moscow - 15 January 2014  ̶  Despite increased regulation, pricing pressures, and the effects of health care reform in many countries, the global life sciences sector is exhibiting resilience and reinvention as it employs new research and development (R&D) and business models to cost-effectively deliver innovation, value, and improved patient outcomes. This is according to Deloitte Touche Tohmatsu Limited’s (DTTL) new report, Global life sciences outlook: Resilience and reinvention in a changing marketplace.

The report outlines the top issues facing global life sciences stakeholders, provides a snapshot of activity in a number of geographic markets, and suggests considerations for companies as they seek to grow revenue and market share in 2014 and beyond.

John Rhodes, DTTL global life sciences sector leader, says: “In 2013, the life sciences sector–comprised of the pharmaceutical, biotechnology, and medical technology segments–was less impacted by the recent global economic uncertainty than other sectors. However, it is facing reimbursement pressure from escalating costs and overwhelmed health systems across the world. Still, an overview of recent sector performance shows that it is favorably positioned to achieve success in the next few years through increased innovation and value delivery.”

Oleg Berezin, CIS Health Care & Life Sciences Group Leader, adds: “The main issue facing the Russian pharmaceutical market is still the effects of the Russian government’s policy regarding it, which is aimed at increasing the proportion of medicines produced in Russia. The proportion of imported medicines is currently dropping, but slowly, and the share remains at just under 80%. On one hand, foreign pharmaceutical companies are greatly interested in maintaining a presence and developing on the Russian market due to the double-digit growth of the market and its potential to grow even further, but on the other hand, problems inherent in the legislation on the trade of medicines, corruption and higher production costs in Russia compared to other countries are all playing a part in limiting foreign investments into the Russian market.

Nevertheless, it is more than likely that, sooner or later, foreign pharmaceutical companies will have to make a decision on whether or not to localise manufacturing in Russia, or they may lose their share in the government procurement market, which is currently over 25% in monetary terms. This follows the proposal by the Russian government to introduce a number of limitations on government procurement of imported medicines, which, incidentally, does not contradict Russia's obligations before the WTO. Thus, aside from increasing the proportion of medicines produced in Russia, the government is attempting to solve a number of issues that it faces under various programmes to provide the population with medicines whose costs are steadily increasing, resulting in the need to introduce further measures aimed at curbing the growth of, or reducing, the prices of medicines, promoting their more rational use, and ensuring their safety, effectiveness and high quality.”

Sector issues in 2014

Among drivers for growth in the global life sciences sector are an aging population, rising incidence of chronic diseases, technological advancements and product innovation, and certain anticipated impacts from health care reform provisions including increases in government funding and insurance coverage. Yet companies also face four major issues in 2014: navigating health care reform; delivering innovation and value; complying with regulatory changes; and operating in a smaller and connected world. The challenges and opportunities emanating from each of these areas can be both global and market-specific.

1. Navigating global health care reform

Countries including the United States, China, Brazil, Germany, France, and the United Kingdom have recently passed substantial legislation that is accelerating the transformation of global health care from a volume- to value-based marketplace, and significantly impacting the life sciences sector. Companies know that changes emanating from health care reform are important, but some are struggling with how to respond. Those organizations that are able to understand and adapt to reform’s challenges and opportunities are likely to be the leaders in the coming years.

2. Delivering innovation and value

A major challenge for life sciences companies is how to productively turn innovation into commercial products. Many innovations require more than traditional small-molecule chemistry or large-molecule-based biology; they tend to require expertise in a number of scientific disciplines. Consequently, there is considerable multi-disciplinary activity occurring around today’s life sciences innovation, which requires collaboration and cooperation, both characteristics of new risk-sharing business models. Increasingly, companies large and small, domestic and international, are engaging in joint ventures, partnerships, and acquisitions to fulfill their R&D and product pipeline objectives.

3. Complying with regulatory changes

Regulatory compliance is a critical issue, particularly in emerging markets such as Southeast Asia, India, and Latin America. Noncompliance can be costly: It can expose an organization to revenue losses, reputational risks, and patient safety issues or, worse, criminal sanctions against individual employees that can jeopardize the future of an entire business unit or company. Compliance issues facing life sciences companies big and small include government policies and mandates, drug safety, counterfeiting, information security and privacy, intellectual property protection, corruption, and M&A/JV and other third-party risks.

4. Operating in a smaller and connected world

Global life sciences players increasingly operate in a smaller and connected world, which presents both opportunities and challenges. Among drivers for growth are an aging population, rising incidence of chronic diseases, technological advancements and product innovation, and certain anticipated impacts from health care reform provisions including increases in government funding and insurance coverage. Opportunities in emerging markets could continue to be a driver, although many companies are looking more cautiously at these markets due to slowing growth and other pressures.

“Despite encouraging economic and demographic trends, life sciences companies’ growth prospects are being tempered by a number of challenging marketplace and enterprise issues. The sector will need to respond appropriately by incorporating global knowledge and resources with new technologies to offer innovative, differentiated products and services that assist clinicians and benefit consumers,” said Rhodes.
Explore the findings in more detail at www.deloitte.com/2014lifesciencesoutlook.

About Deloitte

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee, and its network of member firms, each of which is a legally separate and independent entity. Please see www.deloitte.com/about for a detailed description of the legal structure of Deloitte Touche Tohmatsu Limited and its member firms.

Deloitte provides audit, tax, consulting, and financial advisory services to public and private clients spanning multiple industries. With a globally connected network of member firms in more than 150 countries, Deloitte brings world-class capabilities and high-quality service to clients, delivering the insights they need to address their most complex business challenges. Deloitte has in the region of 200,000 professionals, all committed to becoming the standard of excellence.

Contacts

Name:
Ekaterina Kutsenko
Company:
Deloitte CIS
Job Title:
PR Supervisor
Phone:
+7 (495) 787 06 00
Email
ekutsenko@deloitte.ru
Stay connected:
Get connected
Share your comments

 

More on Deloitte Russia
Learn about our site